Put Quality Ahead Of Cost In Adverse Event Reporting Automation

By John Price, Ph.D.

In 2021, quality became the primary criterion for automating pharmacovigilance (PV) workloads according to the findings of Arriello’s second annual transatlantic survey into the industry’s PV automation intentions. Barriers to automation persisted, including fear for human jobs, along with validation issues. Life sciences companies’ plans to invest in smart solutions to help handle rising pharmacovigilance workloads may have seen delay due to the pandemic, but there are clear signs that these plans remain a priority.